常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-44.70/-1.15
|
|
企业价值
12.18M
|
| 资产负债 |
|
每股账面净值
-3.24
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
42.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/16 02:43 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea. |

6.27 
